Drug Trial Radar · NCT07270146
Effectiveness and Safety of Guilu Erxian Oral Liquid in the Treatment of Oligozoospermia and Asthenospermia With Syndrome of Shen (Kidney) Essence Deficiency
Last checked: Nov 20, 2026Latest source record: Dec 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
360
Actual
Start
Oct 8, 2022
Primary completion
Feb 10, 2025
Study completion Feb 10, 2025
Sponsor
- Lead sponsor
- DongE E Jiao Coporation LimitedIndustry
- Sponsor type
- Industry
- First posted
- Dec 8, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 22 years, up to 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main function of Guilu Erxian Oral Liquid is to warm the shen (kindney) and replenish essence. It is used for chronic shen (kindney) deficiency, waist and knee weakness, spermatorrhea and impotence. The treatment of deficiency of kidney essence and asthenospermia is to invigorate the shen (kindney) and replenish the essence, nourish the shen (kindney) and assist the essence. The idea of combining traditional Chinese and western medicine is to move the yang and calm the yin, and traditional Chinese medicine is mainly to invigorate the shen (kindney) and replenish the essence. In order to better provide the basis for clinical medication and meet the treatment needs of oligozoospermia and asthenospermia, this trial is intended to evaluate the effectiveness and safety of Guilu Erxian oral liquid in treating oligozoospermia and asthenospermia with Syndrome of Shen (Kidney) Essence Deficiency subjects.
Conditions
- Mild and Moderate Oligozoospermia Asthenospermia or Oligoasthenospermia and the Syndrome Differentiation Type is Shen (Kidney) Essence Deficiency
Interventions
Guilu Erxian Oral LiquidDrug
Guilu Erxian Oral Liquid+Wuzi Yanzong Oral Liquid Simulator
Wuzi Yanzong oral liquidDrug
Wuzi Yanzong oral liquid+Guilu Erxian oral liquid simulator
Primary outcomes
What the sponsor says the trial is designed to measure.
- Total number of anterograde motile sperm (TPMSC)Time frame: 4,8,12 weeks after medical treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Xi Yuan Hospital of China Academy of Chinese Medical Sciences
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.